The Intermediate Conductance Calcium Activated Potassium Channel Protein 4 pipeline drugs market research report outlays comprehensive information on the Intermediate Conductance Calcium Activated Potassium Channel Protein 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Intermediate Conductance Calcium Activated Potassium Channel Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Respiratory, Immunology, and Musculoskeletal Disorders which include the indications Cardiovascular, Arrhythmias, Idiopathic Pulmonary Fibrosis, Asthma, Psoriasis, Autoimmune Disorders, Rheumatic Disorders, and Fibrosis. It also reviews key players involved in Intermediate Conductance Calcium Activated Potassium Channel Protein 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Intermediate Conductance Calcium Activated Potassium Channel Protein 4 pipeline targets constitutes close to ten molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 3, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Intermediate Conductance Calcium Activated Potassium Channel Protein 4 overview
Intermediate conductance calcium-activated potassium channel protein 4, also known as KCa3.1 or IK1, is a protein that plays a role in ion channel regulation and is involved in various physiological processes. It is a member of the KCa3.1 subfamily of calcium-activated potassium channels. The activation of KCa3.1 is highly sensitive to changes in intracellular calcium levels, making it a key player in cellular responses to calcium signaling.
For a complete picture of Intermediate Conductance Calcium Activated Potassium Channel Protein 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
